Report Details

Home / Reports / Healthcare and Pharmaceutical / Global IL-17 Biologics Market (2023 Edition): Analysis By Indication (Psoriasis, Psoriatic ...

Global IL-17 Biologics Market (2023 Edition): Analysis By Indication (Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis), By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights and Forecast (2024-2030)

Category: Healthcare and Pharmaceutical

Publish Date: November 2023

No. of Pages: 170

Format: Pdf

  • USD

Licensing options

Executive Summary

Azoth Analytics has released a research report titled “Global IL-17 Biologics Market (2023 Edition)” which provides a complete analysis of the Global IL-17 Biologics industry in terms of market segmentation By Indication (Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis), By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region and By Country. The data has been presented for the year 2022, the estimates for 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC) and 9 countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, Australia). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global IL-17 Biologics Market is expected to generate USD 10.9 Billion by the end of 2030, up from USD 4.37 Billion in 2022. A favourable growth element for the global IL-17 Biologics market is the increasing prevalence of autoimmune and inflammatory diseases, the effectiveness of these drugs in managing these conditions, and the demand for innovative treatments. During the forecast period, 2024-2030, Global IL-17 Biologics is expected to expand at a CAGR of 12.3 %. The implementation of patient support programs, including financial assistance, educational resources, and access to healthcare professionals, enhanced patient adherence and overall satisfaction with IL-17 biologics. These programs are pivotal in ensuring the success of these treatments.

According to the National Stem Cell Foundation, nearly 4% of the world’s population is affected by one of more than 80 different autoimmune diseases. Autoimmune diseases represent the third most common cause of chronic illness in the United States. For unknown reasons, the prevalence of autoimmune diseases is increasing. The use of IL-17 inhibitors in these autoimmune disorders reflects the versatility and potential of this class of biologics in managing various conditions characterized by immune system dysregulation and inflammation.  

Advancements in monoclonal antibody engineering have led to the development of highly targeted IL-17 biologics. Techniques like antibody humanization and affinity maturation help create more effective and specific biologics with reduced side effects.

To ensure the long-term safety and efficacy of IL-17 biologics, innovative immunogenicity testing methods have been developed to monitor and manage immune responses to these treatments. These tests play a crucial role in detecting the development of anti-drug antibodies, thereby maintaining treatment effectiveness. Technological advancements have led to the development of innovative drug delivery systems for IL-17 biologics. For instance, autoinjectors have been created to make self-administration easier for patients. Cosentyx (Secukinumab) is available in a pre-filled syringe or autoinjector, enhancing patient convenience.

The IL-17 biologics market is expanding as these drugs receive regulatory approvals for additional autoimmune disease indications. For instance, Secukinumab was initially approved for treating psoriasis and later received approval for ankylosing spondylitis and psoriatic arthritis, broadening its market potential. The growth in indications increases the patient population eligible for IL-17 biologics.

Scope of the Report

• The report analyses the IL-17 Biologics Market by Value (USD Million).  

• The report presents the analysis of the IL-17 Biologics Market for the year 2022, estimates of 2023 and the forecast period of 2024-2030.  

• The report analyses the IL-17 Biologics Market by Indication (Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis).

• The report analyses the IL-17 Biologics Market by Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.  

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.  

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Eli Lilly and Company, UCB and AstraZeneca PLC.

One can also purchase any particular sections from this report. Please send us an email to with your order details.

Need More Help? Contact us Right now!

No matter the hour, we’re here to help.

Contact us now!